An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
暂无分享,去创建一个
J. Benítez | A. Antoniou | H. Nevanlinna | U. Hamann | A. Meindl | T. Heikkinen | G. Pita | P. Radice | P. Peterlongo | A. Jakubowska | J. Lubiński | D. Yannoukakos | L. McGuffog | A. Osorio | C. Engel | O. Díez | M. Pollán | G. Llort | C. Cybulski | B. Peissel | T. Dębniak | N. Arnold | D. Niederacher | S. Preisler‐Adams | J. Loud | A. Tołoczko‐Grabarek | R. Schmutzler | B. Versmold | W. Hofmann | D. Gadzicki | P. Mai
[1] F. Schmitt,et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer , 2008, BMC Cancer.
[2] J. Peterse,et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.
[3] Georgia Chenevix-Trench,et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.
[4] Alison M Dunning,et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk , 2007, Breast Cancer Research.
[5] Jinko Graham,et al. hapassoc: Software for Likelihood Inference of Trait Associations with SNP Haplotypes and Other Attributes , 2006 .
[6] M. Urioste,et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers , 2006, Human mutation.
[7] J. Chang-Claude,et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes , 2005, Genetic epidemiology.
[8] P. Ongusaha,et al. BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest , 2003, Oncogene.
[9] T. Rebbeck,et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? , 2003, Journal of Medical Genetics.
[10] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[11] E. Imyanitov,et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition , 2003, International journal of cancer.
[12] M. Spitz,et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.
[13] E. Biros,et al. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. , 2002, Lung cancer.
[14] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[15] T. Rebbeck,et al. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. , 1998, Anticancer research.
[16] I. Bleiweiss,et al. p53 haplotype determination in breast cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[17] A. P. Damin,et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. , 2006, Cancer detection and prevention.
[18] P. J. Huber. The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .